What are the best steps to validating antibodies for use in therapeutics? How can researchers find the right antibody for new targets such as GPCRs? What is needed for fast and efficient development of anti-COVID-19 antibodies?
As common challenges in therapeutic antibody discovery are experienced across the field, companies are finding ways to innovate, using new methods and technologies such as AI and machine learning.
This Antibody Therapeutics eBook gathers industry insights exploring the latest approaches and tools for therapeutic antibody discovery, including whitepapers and best practice presentations.
Read or download the report above (or click here).
- Rapid Discovery of Antibodies to Integral Membrane Proteins: A CXCR5 Seven Transmembrane Receptor Case Study: This article explores the latest work on creating anti-GPCR therapeutics by Distributed Bio, as presented at the Antibody Engineering & Therapeutics conference.
- GenScript ProBio’s ProSpeed™ accelerate anti-COVID-19 neutralizing antibody leads discovery with sub-nM IC50: This whitepaper by Genscript explains how its leading single B cell screening platform has been used to accelerate discovery of neutralizing antibodies for treatment, prophylaxis, and detection of SARS-CoV-2.
- Human Monoclonal Antibodies for SARS-CoV-2: We look back at the highlights of an insightful presentation on single cell technologies for the isolation of human monoclonals, the molecular basis for SARS-CoV-2 neutralization, and antibody synergistic exploration by James Crowe Jr., Director at Vanderbilt Vaccine Center.
- TARGATT™ Unique Technology for Antibody Discovery and Screening: In this whitepaper, Applied StemCell presents case studies in which its TARGATT™ gene editing technology enabled an irreversible, site-specific gene insertion at a safe-harbor locus.